Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Fountain Healthcare Partners is a prominent venture capital firm specializing in the life sciences sector. Founded in 2008 by Dr. Manus Rogan and Aidan King, the firm operates from Dublin, Ireland, and New York, USA. It is recognized as Ireland's largest dedicated life sciences VC fund, managing over €425 million in assets across multiple funds. The firm has established itself as a key player in the venture capital landscape, focusing on seed and early-stage investments in specialty pharmaceuticals, biopharmaceuticals, medical devices, and diagnostics.
Fountain Healthcare Partners has a history of supporting innovative healthcare solutions, with a commitment to responsible investment practices. The firm has successfully launched multiple funds, including Fund I in 2008 and Fund III, which raised €118 million, exceeding its €100 million target. The firm’s notable milestones include backing companies that have achieved significant exits, such as Calypso Biotech, which was acquired by Novartis in January 2024.
The investment strategy of Fountain Healthcare Partners centers on the life sciences sector, specifically targeting specialty pharmaceuticals, biopharmaceuticals, medical devices, and diagnostics. The firm focuses on seed and early-stage investments, seeking companies that demonstrate the potential for significant growth and successful exits within a 3 to 6-year timeframe. This approach allows the firm to capitalize on emerging opportunities in the healthcare market.
Fountain Healthcare Partners typically invests in companies that are developing innovative therapies and technologies. The firm emphasizes responsible investment practices and looks for founders who are not only passionate about their projects but also possess a strong understanding of their market. The firm’s deal structure often involves leading or co-leading investment syndicates, providing both capital and strategic guidance to its portfolio companies.
Fountain Healthcare Partners has built a diverse portfolio of companies in the life sciences sector. Notable investments include:
In addition to these current investments, the firm has a history of successful exits, including KaNDy Therapeutics, which was acquired by Bayer in 2020, and Neuravi, acquired by Johnson & Johnson in 2017. These exits highlight the firm’s ability to identify and support companies with high growth potential.
Dr. Manus Rogan, Ph.D, MBA - Managing Partner & Co-Founder. Dr. Rogan has a background in chemistry and extensive experience in venture capital, having previously worked at GSK and Elan Corporation.
Aidan King, MBA, CFA - Managing Partner & Co-Founder. King is a pharmacist with a strong background in marketing and venture capital, also a former employee of Elan Corporation.
Ruthanne Monaghan, FCCA - Partner & CFO. Monaghan brings over 25 years of experience in venture capital and finance to the firm.
Tania Papkovskaia, Ph.D. - Principal. Papkovskaia is a biochemist with a background in healthcare consulting, previously working at Gerson Lehrman Group.
Ena Prosser, Ph.D. - Partner. Prosser is a biotechnologist with experience in life sciences investment, previously associated with Enterprise Ireland.
Justin Lynch, MBA - Partner. Lynch has over 25 years of experience in capital markets, particularly in the medical device sector.
To pitch to Fountain Healthcare Partners, founders should send an email to info@fh-partners.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team background. The firm appreciates clarity and detail in presentations.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In January 2024, Fountain Healthcare Partners announced the acquisition of its portfolio company, Calypso Biotech, by Novartis. This acquisition marks a significant milestone for the firm, showcasing its ability to identify and support companies with high growth potential.
Additionally, the firm has been active in the venture capital space, continuing to expand its portfolio with investments in innovative healthcare solutions. Recent updates indicate ongoing interest in companies that align with their focus on specialty pharmaceuticals and medical devices.
What are the investment criteria for Fountain Healthcare Partners?
The firm primarily invests in seed and early-stage companies within the life sciences sector, focusing on specialty pharmaceuticals, biopharmaceuticals, medical devices, and diagnostics. They look for companies with significant growth potential and a clear path to exit within 3 to 6 years.
How can founders apply or pitch to Fountain Healthcare Partners?
Founders can reach out via email at info@fh-partners.com to initiate a conversation. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Fountain Healthcare Partners different from other VC firms?
Fountain Healthcare Partners is distinguished by its exclusive focus on the life sciences sector and its commitment to responsible investment practices. The firm leverages its extensive industry expertise and network to provide strategic guidance to portfolio companies.
What is the geographic scope of Fountain Healthcare Partners' investments?
The firm primarily invests in private European companies but is also selective about opportunities in the US and public companies, allowing for a broader investment strategy.
What is the typical check size for investments?
While specific check sizes are not disclosed, Fountain Healthcare Partners focuses on seed and early-stage investments, which typically range from several hundred thousand to several million euros, depending on the company’s needs and growth potential.
What kind of post-investment involvement does Fountain Healthcare Partners have?
The firm actively engages with its portfolio companies, providing strategic guidance, industry expertise, and access to a broad network of resources to support their growth and success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.